Search results
Found 28 matches for
Akbar Group: Extracellular Vesicles in Cardiovascular, Inflammatory and Metabolic Disease
Division of Cardiovascular Medicine
The Akbar Lab is interested in defining the therapeutic and diagnostic potential of extracellular vesicles for immunomodulation and precision medicine in cardiovascular, metabolic, and inflammatory diseases.
Tyler Group
Division of Cardiovascular Medicine Oxford Centre for Clinical Magnetic Resonance Research
Development and Application of Cardiac Magnetic Resonance Imaging and Spectroscopy
Pavlides Group: Quantitative MR and liver disease
Division of Cardiovascular Medicine
Our group investigates how MR techniques can be used to improve the care of patients with liver disease. The scope of our work is broad and ranges from evaluation of mature MR techniques in large multicentre studies, to proof-of-concept studies using new methods, or new clinical applications of existing technologies.
Mahmod group
Cardiovascular Clinical Research Facility Division of Cardiovascular Medicine Oxford Centre for Clinical Magnetic Resonance Research
Our expertise is in clinical trials, whereby we aim to discover novel treatments for improving the health of patients with cardiac diseases. We use cardiovascular magnetic resonance imaging (CMR) and spectroscopy techniques to improve our understanding of myocardial metabolism and function, and for early detection of cardiac abnormalities in cardiomyopathy, heart failure, valve disease and diabetes. We use cardiopulmonary exercise test to understand cardiovascular exercise physiology, by studying how oxygen and other nutrients are used by the heart during exercise. We work closely with multidisciplinary research teams including MR physicists, biomedical engineers and other cardiac imaging experts in the UK and elsewhere in the world.
Lewandowski Group: Developmental Systems Physiology
Cardiovascular Clinical Research Facility Division of Cardiovascular Medicine Oxford Centre for Clinical Magnetic Resonance Research
Our group focuses on understanding how alterations to early human development affect long-term disease risk and how to reduce risk through nutritional and lifestyle interventions. Disruptions to normal development, including exposure to pregnancy complications such as being born preterm, are risk factors for early heart failure, stroke and cardiovascular events. To study early developmental changes, we use multi-modality imaging, activity monitoring, questionnaire data and birth records, as well as blood sample collection to study cellular pathways in fetal through to young adult human cohorts.
Neubauer Group: Oxford Centre for Clinical Magnetic Resonance Research
Division of Cardiovascular Medicine Oxford Centre for Clinical Magnetic Resonance Research
OCMR uses sophisticated cardiac MR imaging and spectroscopy methods to phenotype cardiovascular disease – in small-scale proof-of-principle studies, large-scale multicentre clinical trials and ultra-large scale population imaging programmes. As well as running their own research programmes, OCMR serves as a collaboration partner to any group wanting to strengthen their clinical research with state of the art non-invasive phenotyping tools.
Redwood Group: Cardiac Contractility
Division of Cardiovascular Medicine
Defining important functional paradigms that lead to inherited cardiomyopathies, in search of novel treatments.
Ferreira Group: Quantitative cardiac magnetic resonance myocardial tissue characterisation
Division of Cardiovascular Medicine Oxford Centre for Clinical Magnetic Resonance Research
We have expertise in the study of heart disease using cardiovascular magnetic resonance (CMR), particularly quantitative techniques such as myocardial T1-mapping.
Betts Group: Cardiac Rhythm Management
Division of Cardiovascular Medicine
The CRM group’s principal research interests are the treatment of abnormal heart rhythms and the resynchronisation of abnormal electrical conduction in heart failure patients. There is a particular focus on the use of novel and emerging technologies.
Ashrafian Group: Experimental Therapeutics and Clinical Pharmacology
Division of Cardiovascular Medicine
Channon Group: Cardiovascular functional genomics and redox signalling
Division of Cardiovascular Medicine
We work to understand how early changes in cells of the cardiovascular system, such as endothelial cells and leukocytes, are related to cardiovascular disease, with a particular focus on redox biology.
Watkins Group: Inherited Heart Muscle Disease Group
Division of Cardiovascular Medicine
Using human genetics and functional genomics to understand inherited heart disease
Inherited Heart Disease Service
Division of Cardiovascular Medicine
We make about 1600 patient contacts a year with those who have, or are at risk of having, an Inherited Cardiac Condition (eg cardiomyopathies and inherited arrhythmias) across all age ranges. We provide cardiology screening (ECG, Echocardiography) and clinical genetics during an initial single clinic visit, and provide telephone and e-mail support throughout the working week. We have made internationally recognised contributions in this area, in particular the use of cardiac MRI in diagnosis, and understanding of the underlying genetic basis of Inherited Cardiac Conditions.
Leeson Group: Preventive Cardiology Research Group
Cardiovascular Clinical Research Facility Division of Cardiovascular Medicine
Our aim is to develop better ways to identify early disease and improve cardiovascular health for young people. This is achieved by undertaking work in three areas: (1) Identification of novel markers of early disease to better understand how disease becomes established (2) Performing cardiovascular prevention trials in young adults to understand how to modify early disease and improve health (3) Application of artificial intelligence to imaging and research datasets to identify next generation imaging and management approaches.
Banning Group
Division of Cardiovascular Medicine
Use of minimally invasive techniques to improve heart function.
Bhattacharya Group: Developing novel therapeutics for inflammatory diseases
Division of Cardiovascular Medicine
Our goals are to develop therapeutics targeting the chemokine network in inflammatory diseases affecting the heart, blood vessels and other organ systems.
Lygate Group: Cardiac Energetics and Integrative Physiology
Division of Cardiovascular Medicine
We study how the heart meets its high and variable energy demands in order to identify novel strategies that may be beneficial in disease.
Carnicer Group
Division of Cardiovascular Medicine
Nitric oxide regulation of cardiac function, metabolism and inflammation in diabetes.
Gehmlich group: Biomechanical stress signalling in the heart and its role in cardiomyopathies
Division of Cardiovascular Medicine
We research genetic diseases of the heart (cardiomyopathies) that can lead to sudden cardiac death. An example of an individual with cardiomyopathy is the professional football player Fabrice Muamba, who collapsed on the pitch and had to be resuscitated. He was fortunate to survive his cardiac arrest and his case was featured in the media.
Choudhury Group: Understanding Inflammatory processes in Atherosclerosis and Acute Myocardial Infarction
Acute Multidisciplinary Imaging and Interventional Centre Division of Cardiovascular Medicine
This translational science laboratory aims to understand the functionally important heterogeneity in human cardiovascular disease to allow stratification of pathology and enable targeted therapies.